Scienture Holdings, Inc. - Common Stock (SCNX)
1.7750
-0.8250 (-31.73%)
NASDAQ · Last Trade: Oct 24th, 9:57 AM EDT
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via Chartmill · October 24, 2025
Via Benzinga · October 24, 2025
Via Benzinga · October 24, 2025
Major U.S. indices closed higher on Thursday, with the Dow Jones Industrial Average up 0.3% at 46,734.61, the S&P 500 advancing nearly 0.6% to 6,738.44.
Via Benzinga · October 23, 2025
Via Benzinga · October 23, 2025
Via Benzinga · October 23, 2025
Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · October 23, 2025
Discover the most active stocks in Thursday's session. Stay informed about the stocks that are generating the most trading volume!
Via Chartmill · October 23, 2025
Shares of Scienture Holdings, Inc. (NASDAQ: SCNX) are rising Thursday after the company announced the start of commercial sales for Arbli.
Via Benzinga · October 23, 2025
Via Benzinga · October 23, 2025
Let's have a look at the stocks with an unusual volume in today's session.
Via Chartmill · October 23, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · October 23, 2025
Scienture has commenced selling Arbli, the first FDA-approved ready-to-use liquid losartan formulation.
Via Stocktwits · October 23, 2025
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill · October 23, 2025
Via Benzinga · October 23, 2025
Discover the top movers in Thursday's pre-market session and stay informed about market dynamics.
Via Chartmill · October 23, 2025
Scienture launches Arbli, the first FDA-approved liquid losartan, expanding hypertension treatment access across US healthcare institutions.
Via Benzinga · October 23, 2025
Via Benzinga · October 21, 2025
Scienture Holdings, Inc. announced GPO agreements for its new drug, Arbli, providing access to over 2,500 healthcare institutions and plans to expand further.
Via Benzinga · October 1, 2025
Scienture's Arbli, the first ready-to-use liquid losartan, gains formulary access with coverage for over 100 million lives and discussions for broader access.
Via Benzinga · September 16, 2025
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Via Chartmill · August 14, 2025
Via Benzinga · August 14, 2025
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · August 14, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.
Via Chartmill · August 14, 2025
Via Benzinga · August 14, 2025